960003-13-8

Basic information

• Product Name: methyl N-[(2-chlorophenyl)carbonyl]-4-[1-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-phenylalaninate
• Synonyms: methyl N-[(2-chlorophenyl)carbonyl]-4-[1-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-phenylalaninate
• CAS NO: 960003-13-8
• Molecular Weight: 492.017
• Mol File: 960003-13-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl N-[(2-chlorophenyl)carbonyl]-4-[1-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-phenylalaninate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N-[(2-chlorophenyl)carbonyl]-4-[1-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-phenylalaninate(960003-13-8)
• EPA Substance Registry System: methyl N-[(2-chlorophenyl)carbonyl]-4-[1-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-phenylalaninate(960003-13-8)

Safety Data

• Hazardous Substances Data: 960003-13-8(Hazardous Substances Data)

Upstream product

• 61323-17-9 2-bromo-1,8-naphthyridine 
• 959992-99-5 methyl N-(tert-butoxycarbonyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-L-phenylalaninate 
• 959992-97-3 methyl N-(tert-butoxycarbonyl)-4-[3-(1,8-naphthyridin-2-yl)prop-1-en-1-yl]-L-phenylalaninate 
• 959992-96-2 2-prop-2-en-1-yl-1,8-naphthyridine 
• 959993-00-1 methyl 4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-L-phenylalaninate 
• 118-91-2 ortho-chlorobenzoic acid 

Relevant articles and documents

N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS

The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.